PMID- 27778096
OWN - NLM
STAT- MEDLINE
DCOM- 20170313
LR  - 20181113
IS  - 1434-9949 (Electronic)
IS  - 0770-3198 (Linking)
VI  - 36
IP  - 3
DP  - 2017 Mar
TI  - The dimeric form of HLA-G molecule is associated with the response of early 
      rheumatoid arthritis (ERA) patients to methotrexate.
PG  - 701-705
LID - 10.1007/s10067-016-3454-z [doi]
AB  - A growing body of evidence indicates a possible involvement of HLA (human 
      leukocyte antigen)-G antigens in rheumatoid arthritis (RA), mainly in the HLA-G 
      dimeric isoform, the most active HLA-G form with the strongest immunosuppression, 
      that showed an excellent anti-inflammatory effect in collagen-induced arthritis 
      model mice. However, the relevance of HLA-G dimers in RA response to methotrexate 
      (MTX) treatment is still unknown. We analyzed the HLA-G dimers' amount in plasma 
      samples from early rheumatoid arthritis (ERA) patients before MTX therapy and 
      evaluated the role of these molecules as biomarker of the different response to 
      the treatment. Plasma sHLA-G levels were detected by ELISA, and HLA-G dimeric and 
      monomeric forms were revealed by Western blot in 12 MTX responder (reaching DAS28 
      remission <2.6) and 8 MTX non-responder (DAS28 >/=5.1) patients before the therapy. 
      The response to MTX was evaluated after 6 months of treatment. All ERA patients 
      reaching remission showed higher plasma sHLA-G levels and the 78 kDa HLA-G 
      dimeric form. Unresponsive ERA patients were characterized by lower plasma sHLA-G 
      levels, and only one patient presented the 78 kDa HLA-G dimeric form (DAS28 5.1). 
      Our preliminary results support the hypothesis that in ERA patients, sHLA-G and, 
      in particular, the presence of the dimeric form in plasma samples before MTX 
      therapy could be an a priori biomarker for the response to MTX treatment.
FAU - Rizzo, Roberta
AU  - Rizzo R
AD  - Department of Medical Sciences, Section of Microbiology and Medical Genetics, 
      University of Ferrara, Via Luigi Borsari, 46 44121, Ferrara, Italy. rbr@unife.it.
FAU - Farina, Ilaria
AU  - Farina I
AD  - Section of Haematology and Rheumatology, University of Ferrara, Ferrara, Italy.
FAU - Bortolotti, Daria
AU  - Bortolotti D
AD  - Department of Medical Sciences, Section of Microbiology and Medical Genetics, 
      University of Ferrara, Via Luigi Borsari, 46 44121, Ferrara, Italy.
FAU - Galuppi, Elisa
AU  - Galuppi E
AD  - Section of Haematology and Rheumatology, University of Ferrara, Ferrara, Italy.
FAU - Padovan, Melissa
AU  - Padovan M
AD  - Section of Haematology and Rheumatology, University of Ferrara, Ferrara, Italy.
FAU - Di Luca, Dario
AU  - Di Luca D
AD  - Department of Medical Sciences, Section of Microbiology and Medical Genetics, 
      University of Ferrara, Via Luigi Borsari, 46 44121, Ferrara, Italy.
FAU - Govoni, Marcello
AU  - Govoni M
AD  - Section of Haematology and Rheumatology, University of Ferrara, Ferrara, Italy.
LA  - eng
PT  - Journal Article
DEP - 20161024
PL  - Germany
TA  - Clin Rheumatol
JT  - Clinical rheumatology
JID - 8211469
RN  - 0 (Antirheumatic Agents)
RN  - 0 (HLA-G Antigens)
RN  - YL5FZ2Y5U1 (Methotrexate)
SB  - IM
MH  - Adult
MH  - Antirheumatic Agents/*therapeutic use
MH  - Arthritis, Rheumatoid/blood/*drug therapy/immunology
MH  - Female
MH  - HLA-G Antigens/*blood
MH  - Humans
MH  - Male
MH  - Methotrexate/*therapeutic use
MH  - Middle Aged
MH  - Remission Induction
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Disease-modifying anti-rheumatic drugs
OT  - Early rheumatoid arthritis
OT  - Human leukocyte antigen-G
OT  - Methotrexate
EDAT- 2016/10/26 06:00
MHDA- 2017/03/14 06:00
CRDT- 2016/10/26 06:00
PHST- 2016/07/06 00:00 [received]
PHST- 2016/10/13 00:00 [accepted]
PHST- 2016/10/10 00:00 [revised]
PHST- 2016/10/26 06:00 [pubmed]
PHST- 2017/03/14 06:00 [medline]
PHST- 2016/10/26 06:00 [entrez]
AID - 10.1007/s10067-016-3454-z [pii]
AID - 10.1007/s10067-016-3454-z [doi]
PST - ppublish
SO  - Clin Rheumatol. 2017 Mar;36(3):701-705. doi: 10.1007/s10067-016-3454-z. Epub 2016 
      Oct 24.